In today’s briefing:
- Shanghai Fosun Pharmaceutical (2196.HK) – Performance Pain Points and Henlius’ Privatization Outlook
- ASKA Pharmaceutical (4886) | Healthy Returns
- CVM: CRO Selected for Registrational Trial
- MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial
- NRXBF: New Test Results Opens Potential New Market
Shanghai Fosun Pharmaceutical (2196.HK) – Performance Pain Points and Henlius’ Privatization Outlook
- Fosun Pharma is just “a platform” and its performance mainly relies on the contributions of subsidiaries. However, such investment-driven business model has led to the current performance difficulties.
- Although the motivation/underlying logic for Fosun Pharma to privatize Henlius are solid, we don’t know how this privatization ranks in terms of strategic significance of capital operations within Fosun’s system.
- If, for example, Fosun Pharma finds more important acquisitions/capital expenditures, the priority of Henlius’ privatization could fall. So, we think if it takes too long, there may be more uncertainties.
ASKA Pharmaceutical (4886) | Healthy Returns
- ASKA Pharmaceutical Holdings represents an attractive investment opportunity with substantial upside potential
- The company combines solid growth, strong profitability, and clear avenues for shareholder value enhancement.
- With Nippon Active Value’s increasing involvement and the stock trading at deeply discounted valuations, ASKA is well-positioned for a re-rating.
CVM: CRO Selected for Registrational Trial
- CEL-SCI is developing two platforms: Multikine and LEAPS.
- Multikine has completed a Phase 3 trial for head and neck cancer while LEAPS is conducting preclinical studies for RA, Pandemic Flu and breast cancer.
- In June 2021, CEL-SCI reported selected data from its IT-MATTERS trial demonstrating a benefit in the low PD-L1, non-chemotherapy population.
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial
- On December 5, 2024, MediciNova, Inc. (MNOV) announced a study update and interim analysis from the Phase 2b/3 COMBAT-ALS trial were scheduled to be presented at the 35th International Symposium on ALS/MND.
- As of Nov.
- 15, 2024, 217 participants had been enrolled and 183 participants were assigned to either MN-166 or placebo.
NRXBF: New Test Results Opens Potential New Market
- NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.
- The technology involved also has the potential to more efficiently get other treatments to the needed area.
- The company is also expanding its potential treatments with ExoPTEN and announced preclinical results that showed promise in repairing optic nerve damage.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
